To test if inhibition of EHMT1 and EHMT2 enhances the anticancer effect of imatinib in CML, we investigated the cytotoxicity of imatinib in the presence or absence of BIX01294. The gene discussed is EHMT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.